1Gray PW, Goeddel DV. Cloning and expression of murine immune interferon eDNA. Proc Natl Acad Sci USA. 1983,80:5842-5846.
2Kramer MJ,Dennin R, Kramer C, et al. Cell and virus sensitivity studies with recombinant human apha interferons. J Interferon Res, 1983,3:425-435.
3Fish EN, Banerjee K, Stebbing N. Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells. Biochem Biophys Res Commun, 1983, 112:537-546.
4Grant S, Bhalla K, Weinstein IB, et al. Differential effect of recombinant human leukocyte interferon on human leukemic and normal myeloid progenitor cells. Beichem Biophys Res Commun, 1982,108: 1048-1055.
5Chapekar MS, Glazer RI. Effects of fibroblast and recombinant leukocyte interferons and double-stranded RNA on ppp(2'-5' )An synthesis and cell proliferation in human colon carcinoma cells in vitro. Cancer Res, 1983,43:2683-2687.
6Wills R J, Spiegel HE, Soike KF. Pharmacokinetics of recombinant alpha A interferon following I.V. infusion and bolus I.M. and P.O. administration to African green monkeys. J Interferon Res, 1984,4:399-409.
7Wills R J, Dennis S, Spiege HE, et al. Interferon kinetics and adverse reactions after intravenous intramuscular and subcutaneous injection. Clin Pharmacol Ther, 1984,35:722-727.
8Gibson DM, Cotler S, Spiege HE, et al. Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog. J Interferon Res, 1985,5 :403-408.
9Trown PW, Wills R J, Kamm JJ. The preclinical development of Roferon-A. Cancer, 1986,57 (Suppl) : 1648-1656.
10Ronneberger H, Hilferhaus J. Toxicity studies with human fibroblast interferon. Arch Toxicol, 1983,6 (Suppl):391-394.
